Survival for Patients with Radiographically Occult Metastatic Pancreatic Cancer in the Era of Modern Multiagent Chemotherapy.
作者信息
Eckhoff Austin M, Kanu Elishama, Bao Matthew, Blazer Dan G, Zani Sabino, Lidsky Michael E, Allen Peter J, Nussbaum Daniel P
机构信息
Department of Surgery, Duke University, Durham, NC, USA.
出版信息
Ann Surg Oncol. 2023 Jun;30(6):3194-3196. doi: 10.1245/s10434-023-13318-5. Epub 2023 Mar 14.
Abstract
摘要
相似文献
1
Survival for Patients with Radiographically Occult Metastatic Pancreatic Cancer in the Era of Modern Multiagent Chemotherapy.
Ann Surg Oncol. 2023 Jun;30(6):3194-3196. doi: 10.1245/s10434-023-13318-5. Epub 2023 Mar 14.
2
Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols.在现代联合治疗方案时代之前，接受序贯化疗治疗的晚期胰腺癌患者的长期预后。
J Cancer Res Clin Oncol. 2019 Feb;145(2):445-455. doi: 10.1007/s00432-018-2789-z. Epub 2018 Nov 14.
3
Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.接受系统治疗的复发性胰腺癌患者的总生存：一项回顾性研究。
BMC Cancer. 2019 May 17;19(1):468. doi: 10.1186/s12885-019-5630-4.
4
Pancreatic ductal adenocarcinoma: metastatic disease.胰腺导管腺癌：转移性疾病。
Clin Transl Oncol. 2017 Dec;19(12):1423-1429. doi: 10.1007/s12094-017-1690-6. Epub 2017 Jun 16.
5
Phase I/II Study: Experience with the Late Onset of Acute Pancreatitis after the Start of Chemotherapy with Gemcitabine Plus nab-Paclitaxel for Metastatic Pancreatic Cancer.I/II期研究：吉西他滨联合白蛋白结合型紫杉醇治疗转移性胰腺癌化疗开始后急性胰腺炎延迟发作的经验
Intern Med. 2019 Oct 15;58(20):2957-2962. doi: 10.2169/internalmedicine.2362-18. Epub 2019 Jun 27.
6
Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.纳米脂质体伊立替康联合氟尿嘧啶和亚叶酸治疗转移性胰腺导管腺癌二线治疗选择：一项回顾性队列研究。
BMC Cancer. 2021 Nov 3;21(1):1176. doi: 10.1186/s12885-021-08887-1.
7
Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma.CA19-9 达峰时间：确定可切除胰腺导管腺癌患者最佳治疗持续时间的线索。
Cancer Chemother Pharmacol. 2020 Apr;85(4):641-650. doi: 10.1007/s00280-020-04047-7. Epub 2020 Mar 10.
8
Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.转移性胰腺导管腺癌：着眼未来的诊断与治疗
Intern Med J. 2018 Jun;48(6):637-644. doi: 10.1111/imj.13810.
9
KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.转移性胰腺导管腺癌中 KRAS 突变：评估西妥昔单抗联合吉西他滨/奥沙利铂（GEMOXCET）一线治疗疗效的多中心 II 期研究结果。
Oncology. 2011;81(1):3-8. doi: 10.1159/000330194. Epub 2011 Sep 2.
10
Chemotherapy: NAPOLI-1: winning scoop for metastatic pancreatic cancer.化疗：NAPOLI-1研究：转移性胰腺癌的重大突破
Nat Rev Clin Oncol. 2016 Jan;13(1):2-3. doi: 10.1038/nrclinonc.2015.220. Epub 2015 Dec 15.
本文引用的文献
1
A nomogram of preoperative predictors for occult metastasis in patients with PDAC during laparoscopic exploration.用于预测胰腺癌患者腹腔镜探查期间隐匿性转移的术前预测指标列线图。
Gland Surg. 2021 Jan;10(1):279-289. doi: 10.21037/gs-20-605.
2
Incidence and risk factors for abdominal occult metastatic disease in patients with pancreatic adenocarcinoma.胰腺腺癌患者腹部隐匿性转移病的发生率及危险因素。
J Surg Oncol. 2018 Dec;118(8):1277-1284. doi: 10.1002/jso.25288. Epub 2018 Oct 31.
3
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.白蛋白结合型紫杉醇联合吉西他滨治疗胰腺癌可提高生存率。
N Engl J Med. 2013 Oct 31;369(18):1691-703. doi: 10.1056/NEJMoa1304369. Epub 2013 Oct 16.
4
Multimodality imaging of pancreatic cancer-computed tomography, magnetic resonance imaging, and positron emission tomography.胰腺癌的多模态影像学——计算机断层扫描、磁共振成像和正电子发射断层扫描。
Cancer J. 2012 Nov-Dec;18(6):511-22. doi: 10.1097/PPO.0b013e318274a461.
5
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.FOLFIRINOX 对比吉西他滨治疗转移性胰腺癌。
N Engl J Med. 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923.
6
Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma.术前CA 19-9与影像学可切除胰腺腺癌患者分期腹腔镜检查的阳性率
Ann Surg Oncol. 2008 Dec;15(12):3512-20. doi: 10.1245/s10434-008-0134-5. Epub 2008 Sep 10.
Zotero 插件